|
| | Unvaccinated (n = 92) | Vaccinated 1st dose (n = 29) | Vaccinated 2nd dose (n = 38) |
|
| Median age (range) | 37.5 (6–77) years | 40 (20–81) years | 33 (9–62) years |
| Male:female | 1:1 | 1:9 | 0 : 6 |
| Symptomatic (n, %) | 79 (85.9) | 29 (100%) | 36 (94.7%) |
| Fever (n, %) | 60 (65.2%) | 24 (82.8%) | 20 (52.6%) |
| Cough (n, %) | 35 (38%) | 13 (44.8%) | 17 (44.7%) |
| Sore throat (n, %) | 17 (18.5%) | 6 (20.7%) | 14 (36.8%) |
| Body ache (n, %) | 15 (16.3%) | 13 (44.8%) | 19 (50%) |
| Breathlessness (n, %) | 14 (15.2%) | 9 (31%) | 4 (10.5%) |
| Comorbidities (n, %) | 39 (42.4%) | 12 (41.4%) | 7 (18.4%) |
| Malignancies (n, %) | 27 (29.3%) | 1 (3.4%) | 1 (2.6%) |
| Diabetes mellitus (n, %) | 8 (8.7%) | 4 (13.8%) | 2 (5.3%) |
| Hypertension (n, %) | 7 (7.6%) | 5 (17.2%) | 3 (7.9%) |
| Distribution according to municipality |
| Mumbai | 11 (11.9%) | 6 (20.7%) | 7 (18.4%) |
| Palghar | 1 (1.1%) | 0 | 0 |
| Raigad | 57 (61.9%) | 19 (65.5%) | 22 (57.9%) |
| Thane | 23 (25%) | 4 (13.8%) | 9 (23.7%) |
| Type of vaccine (total, AZD1222:BBV152) | 16 (<14 days after the first dose), 11 : 5 | 29, 24 : 5 | 38, 38 : 0 |
| 14–20 days from the 1st dose | | 6 (20.7%) | |
| 21–28 days from the 1st dose | | 4 (13.8%) | |
| 28+ days from the 1st dose | | 12 (65.5%) | |
| 14–20 days from the 2nd dose | | | 6 (15.8%) |
| 21–28 days from the 2nd dose | | | 8 (21.1%) |
| 28+ days from the 2nd dose | | | 24 (63.2%) |
| SARS-CoV-2 genomic sequencing |
| B.1.617.1 | 40 (43.5%) | 14 (48.3%) | 23 (60.5%) |
| B.1.617.2 | 46 (50%) | 15 (51.7%) | 14 (36.8%) |
| B.1.617.3 | 3 (3.2%) | 0 | 0 |
| B.1.1.7 | 1 (1.1%) | 0 | 0 |
| Others | 2 (2.2%) | 0 | 1 (2.6%) |
| CBC (data available in n = 45) | (n = 31) | (n = 9) | (n = 5) |
| Median TLC x 10^9/L (range) | 5.23 (0.27–9.04) | 5.27 (3.39–14.98) | 5.17 (4.68–8.3) |
| Median worst ALC x 109/L (range) | 0.89 (0.11–3.19) | 0.88 (0.36–1.2) | 0.9 (1.3–1.7) |
| Biochemical parameters (data available in n = 45) | (n = 31) | (n = 9) | (n = 5) |
| Median worst CRP mg/L (range) | 2.15 (0.1–32.0) | 1.8 (0.5–16.22) | 2.0 (0.2–3.4) |
| Median highest IL6 pg/mL (range) | 7.8 (0.7–8677) | 14.3 (0.4–69.2) | 8.3 (0.8–16.1) |
| Median worst procalcitonin ng/mL (range) | 0.05 (0.05–151.5) | 0.05 (0.05–0.92) | 0.05 (0.05–0.05) |
| Median worst fibrinogen mg/dL (range) | 345 (197–539) | 361 (248–613) | 349 (284–523) |
| Median worst D-dimer ng/mL (range) | 219 (127–878) | 200 (148–522) | 213 (177–220) |
| Distribution according to the clinical outcome |
| Not hospitalized (WHO score 1–2) | 51 (55.4%) | 17 (58.6%) | 29 (76.3%) |
| Hospitalized, mild disease (WHO score 3–4) | 30 (32.6%) | 9 (31.0%) | 9 (23.7%) |
| Hospitalized, severe disease (WHO score 5–7) | 7 (7.6%) | 3 (10.3%) | 0 |
| Death (WHO score 8) | 4 (4.3%) | 0 | 0 |
|
